SECOND QUARTER REVENUES WERE DOWN FOR A TRI CITIES DRUG MANUFACTURING COMPANY. OFFICIALS WITH BRISTOL TENNESSEE-BASED KING PHARMACEUTICALS SAY TOTAL REVENUES WERE 397 MILLION DOLLARS DURING THE SECOND QUARTER, COMPARED TO 543 MILLION THE SAME TIME LAST YEAR. COMPANY OFFICIALS BLAME THE LOWER NUMBERS ON THE MARKET ENTRY OF GENERIC SUBSTITUTES FOR ALTACE. AS OF JUNE 30TH, THE COMPANY’S CASH AND CASH EQUIVALENTS TOTALED NEARLY 1.1 BILLON DOLLARS. NET REVENUES FROM BRANDED PHARMACEUTICALS WERE DOWN AS WELL. COMPANY OFFICIALS ARE HOPEFUL THE NUMBERS WILL IMPROVE.